LOADING
Nasal Spray Naloxone Gets Closer to Public Availability
June 24, 2015
Share
Adapt Pharma Limited has begun a new drug application (NDA) with the FDA for a nasal spray form of naloxone, which is used in preventing opioid overdose deaths. This submission is a “rolling submission,” meaning that “completed portions . . . [will] be submitted and reviewed by the FDA on an ongoing basis” (NIDA, 2015).
According to the National Institute on Drug Abuse (NIDA), “the only current FDA-approved method of administering naloxone is by injection” (2015), so a nasal delivery system would allow for more widespread availability.
Adapt Pharma Limited is a partner of Lightlake Therapeutics, Inc., a biopharmaceutical company that develops new treatment for addiction. Lightlake Therapeutics has been partnered with NIDA since 2013.
References
National Institute on Drug Abuse (NIDA). (2015). Nasal spray naloxone step closer to public availability. Retrieved from http://www.drugabuse.gov/news-events/news-releases/2015/06/nasal-spray-naloxone-one-step-closer-to-public-availability
Previous Article
Study: Legalization Hasn’t Increased Teen Pot Use
Next Article
Brain Protein Linked to Binge Drinking
Current Issue
Counselor Magazine is the official publication of the California Association of Addiction Programs and Professionals (CCAPP). Counselor offers online continuing education, article archives, subscription deals, and article submission guidelines. It has been serving the addiction field for more than thirty years.
For more information on CCAPP’s many programs, certifications, and career paths, please visit ccapp.us.